Hot Investor Mandate: Japanese VC Invests in Promising Early, Pre-Clinical Stage Technologies Across All Life Science Sectors, Focusing on Companies in USA & Europe

23 Jun

An investment firm in Japan is currently investing from its second fund which had an initial close in 2020. The firm is actively seeking investment opportunities in Seed to Series A rounds, and can invest up to $3M over the company’s lifecycle. The firm is open to companies based in Japan, USA, and Europe.

The firm is interested in cutting edge technologies in all areas of life sciences, and will consider all opportunities in therapeutics, medical devices, diagnostics, and digital health across all indications. As MIJ is an early-stage investor, the firm will consider any technologies in pre-clinical stage of development.

The firm does not have specific company or management team requirements. The firm can act as either a lead or co-investor, but if the company is very early-stage, the firm will expect to have a more active role in supporting the company’s growth and will seek to act as the lead investor. In addition, the firm has partnered with numerous organizations and has a strong network the firm can leverage to provide operational/commercialization support.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: